Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial
Cármen Lúcia Kuniyoshi Rebelatto, Alexandra Cristina Senegaglia, Cláudio Luciano Franck, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial
Morteza Zarrabi, Mohammad Amin Shahrbaf, Masoumeh Nouri, et al.
Stem Cell Research & Therapy (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 43
Cell–cell communication: new insights and clinical implications
Jimeng Su, Ying Song, Zhipeng Zhu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 37
NSP4 and ORF9b of SARS-CoV-2 Induce Pro-Inflammatory Mitochondrial DNA Release in Inner Membrane-Derived Vesicles
Md Imam Faizan, Rituparna Kundu Chaudhuri, Shakti Sagar, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 2969-2969
Open Access | Times Cited: 44
The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials
Shou Zhen Wang, Yiming Li, Bingqing Wang, et al.
Critical Care (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 35
Investigational pharmacological agents for the treatment of ARDS
Katyayini Aribindi, Michelle Lim, Satyan Lakshminrusimha, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 3, pp. 243-277
Closed Access | Times Cited: 9
Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial
Tiantian Li, Bo Zhang, Hui Fang, et al.
EBioMedicine (2023) Vol. 92, pp. 104600-104600
Open Access | Times Cited: 22
Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery
Pedro Silva Couto, Nada Al-Arawe, Igor Salerno Filgueiras, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
The preclinical and clinical progress of cell sheet engineering in regenerative medicine
Danping Hu, Xinyu Li, Jie Li, et al.
Stem Cell Research & Therapy (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 17
Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects
Min Meng, Weiwei Zhang, Shuangfeng Chen, et al.
World Journal of Stem Cells (2024) Vol. 16, Iss. 2, pp. 70-88
Open Access | Times Cited: 6
Cell-based Therapies for Acute Respiratory Distress Syndrome: Where Are We Now?
Gerard F. Curley, Cecilia M. O’Kane, Daniel F. McAuley, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 209, Iss. 7, pp. 789-797
Open Access | Times Cited: 4
Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19
H. Taufiq, Kamal Shaik Fakiruddin, Umaiya Muzaffar, et al.
Therapeutic Advances in Respiratory Disease (2023) Vol. 17
Open Access | Times Cited: 10
Exosomes in COVID‐19 infection: Focus on role in diagnosis, pathogenesis, immunity, and clinical trials
Alhanouf Aljuhani, Omniah Albalawi, Rahaf Albalawi, et al.
Cell Biology International (2023) Vol. 47, Iss. 6, pp. 1049-1067
Closed Access | Times Cited: 9
Stem Cell Extracellular Vesicles as Anti-SARS-CoV-2 Immunomodulatory Therapeutics: A Systematic Review of Clinical and Preclinical Studies
Sarah Hamdy Ahmed, Mohamed Atef AlMoslemany, Kenneth W. Witwer, et al.
Stem Cell Reviews and Reports (2024) Vol. 20, Iss. 4, pp. 900-930
Open Access | Times Cited: 3
Mesenchymal Stem Cells on Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Jinlv Qin, Guizuo Wang, Dong Han
Stem Cell Reviews and Reports (2024) Vol. 20, Iss. 4, pp. 931-937
Closed Access | Times Cited: 3
Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials
Wenming Lu, Longxiang Yan, Xingkun Tang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?
Aidan M. Kirkham, Adrian Bailey, Risa Shorr, et al.
Cytotherapy (2022) Vol. 25, Iss. 3, pp. 341-352
Open Access | Times Cited: 15
Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives
Sabrina Mattoli, M. Schmidt
Advances in Therapy (2023) Vol. 40, Iss. 6, pp. 2626-2692
Open Access | Times Cited: 8
Quality Control Optimization for Minimizing Security Risks Associated with Mesenchymal Stromal Cell-Based Product Development
Cármen Lúcia Kuniyoshi Rebelatto, Lidiane Maria Boldrini Leite, Débora Regina Daga, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12955-12955
Open Access | Times Cited: 8
Mesenchymal Stem Cells in the Treatment of COVID-19
Bei-Cyuan Guo, Kang‐Hsi Wu, Chun‐Yu Chen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14800-14800
Open Access | Times Cited: 8
Effect and safety of mesenchymal stem cells for patients with COVID‐19: Systematic review and meta‐analysis with trial sequential analysis
Zhijing Zhang, Shuai Shao, Xuefeng Liu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Open Access | Times Cited: 7
Safety and efficacy of mesenchymal stem cells in COVID‐19 patients: A systematic review and meta‐analysis
Cai Yan, Minjie Hu, Rongjuan Dai
Immunity Inflammation and Disease (2023) Vol. 11, Iss. 9
Open Access | Times Cited: 7
Loss of socioemotional and occupational roles in individuals with Long COVID according to sociodemographic and clinical factors: Secondary data from a randomized clinical trial
Sandra León-Herrera, Mario Samper-Pardo, Bárbara Oliván‐Blazquez, et al.
PLoS ONE (2024) Vol. 19, Iss. 2, pp. e0296041-e0296041
Open Access | Times Cited: 2
Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial
María Esther Martínez-Muñoz, Concepción Payares‐Herrera, I. Lipperheide, et al.
Bone Marrow Transplantation (2024) Vol. 59, Iss. 6, pp. 777-784
Open Access | Times Cited: 2
Treatment of Acute Respiratory Distress Syndrome Caused by COVID-19 with Human Umbilical Cord Mesenchymal Stem Cells
Tetiana Bukreieva, Hanna Svitina, V.V. Nikulina, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4435-4435
Open Access | Times Cited: 6
Mesenchymal stem cell therapy for COVID-19 infection
Seyyed Mohammad Matin Alavi-Dana, Yazdan Gholami, Mohammadreza Meghdadi, et al.
Inflammopharmacology (2023) Vol. 32, Iss. 1, pp. 319-334
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top